Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer’s disease pathologies
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The distinctive cortical uptake of the tracer 18 F‐FDDNP (2‐(1‐{6‐[(2‐fluoroethyl(methyl)amino]‐2‐naphthyl}ethylidene)malononitrile) in Alzheimer’s disease (AD) is believed to be because of its binding to both neurofibrillary tangles (NFTs) and highly fibrillar senile plaques. We therefore investigated the binding of a tracer concentration of 3 H‐FDDNP to brain sections containing AD hallmark pathologies. Semi‐adjacent sections were labelled with 3 H‐PIB (Pittsburgh compound‐B, 2‐[4′‐(methylamino)phenyl]‐6‐hydroxybenzothiazole) and 14 C‐SB13 (4‐N‐methylamino‐4′‐hydroxystilbene) for comparison. Neocortical sections containing widespread senile plaques and cerebrovascular amyloid angiopathy, produced a sparse and weak labelling following incubation with 3 H‐FDDNP. Furthermore, in sections containing NFTs, there was no overt labelling of the pathology by 3 H‐FDDNP. In contrast, sections labelled with 3 H‐PIB displayed extensive labelling of diffuse plaques, classical plaques, cerebrovascular amyloid angiopathy and NFTs. 14 C‐SB13 produced a broadly similar binding pattern to PIB. Radioligand binding assays employing in vitro generated amyloid‐β peptide fibrils demonstrated a ∼10‐fold reduced affinity for 3 H‐FDDNP (85.0 ± 2.0 nM) compared with 3 H‐PIB (8.5 ± 1.3 nM). These data provide an alternative mechanistic explanation for the observed low cortical uptake of 18 F‐FDDNP in AD; in that the ligand is only weakly retained by the hallmark neuropathology because of its low affinity for amyloid structures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
Imaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104 · cited 1×
“The cerebral concentrations of ligand attained in imaging studies is typically in the low nanomolar range (Mathis et al. 2004; Rowe et al. 2007) and the aim of this study was to determine the histological structures labelled by FDDNP at these tracer concentrations.”
BackgroundPost-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933 · cited 4×
“Finally, the labelling of the HIP formation section (HIP1) with PIB illustrates on a single section the differential sensitivity of the tracer for the hallmark AD pathologies and complements two recent studies, which in part, addressed this issue (Lockhart et al. 2007 and Ikonomovic et al. 2008).”
BackgroundResultInfluentialPike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., Mathis, C. A., Klunk, W. E., Masters, C. L., & Rowe, C. C. (2007) · Brain · doi:10.1093/brain/awm238 · Cited by 789 · cited 1×
“…studies indicates that the maximal cortical uptake of the tracer in AD cases is at most 20% higher when compared with non-demented control cases; in contrast 11C-PIB demonstrates a 100–200% higher cortical uptake in AD cases relative to non-demented controls (Klunk et al. 2004; Pike et al. 2007).”
ResultPIB is a non-specific imaging marker of amyloid-beta (A ) peptide-related cerebral amyloidosis
Lockhart, A., Lamb, J. R., Osredkar, T., Sue, L. I., Joyce, J. N., Ye, L., Libri, V., Leppert, D., & Beach, T. G. (2007) · Brain · doi:10.1093/brain/awm191 · Cited by 302 · cited 24×
“Previous studies indicated that (3)H-PIB associated with this specific Ab pool was only partially displaceable in labelling reactions containing excess unlabelled ligand (Lockhart et al. 2007).”
BackgroundMethodResultInfluentialSelf-citationLockhart, A., Ye, L., Judd, D. B., Merritt, A. T., Lowe, P. N., Morgenstern, J. L., Hong, G., Gee, A. D., & Brown, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412056200 · Cited by 213 · cited 10×
“In vitro characterization of the 3H-FDDNP preparation using Ab fibrils In an effort to further understand the weak labelling of the 3H-FDDNP treated sections (relative to both (3)H-PIB and (14)C-SB13), we investigated the binding properties of the radioligand preparation for in vitro generated Ab fibrils, using a prev…”
BackgroundMethodResultInfluentialSelf-citation
Cited by
Maruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., Zhang, M.-R., Trojanowski, J. Q., Lee, V. M.-Y., Ono, M., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.037 · Cited by 760
Tau PET imaging in neurodegenerative tauopathies—still a challenge
Leuzy, A., Chiotis, K., Lemoine, L., Gillberg, P.-G., Almkvist, O., Rodriguez-Vieitez, E., & Nordberg, A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0342-8 · Cited by 628
Tau imaging: early progress and future directions
Villemagne, V. L., Fodero-Tavoletti, M. T., Masters, C. L., & Rowe, C. C. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70252-2 · Cited by 501
Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program
Beach, T. G., Adler, C. H., Sue, L. I., Serrano, G., Shill, H. A., Walker, D. G., Lue, L., Roher, A. E., Dugger, B. N., Maarouf, C., et al. (2015) · Neuropathology · doi:10.1111/neup.12189 · Cited by 460
Self-citationThe use of PET in Alzheimer disease
Nordberg, A., Rinne, J. O., Kadir, A., & Långström, B. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.217 · Cited by 449
Metadata
- Authors
- Thompson, P. W., Ye, L., Morgenstern, J. L., Sue, L., Beach, T. G., Judd, D. J., Shipley, N. J., Libri, V., & Lockhart, A.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2009-03-18
- Volume
- 109
- Issue
- 2
- Pages
- 623-630
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2082313481
- Cited by
- 137
- References
- 7
- FWCI
- 9.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer’s disease pathologies. https://app.cochat.ai/papers/10.1111/j.1471-4159.2009.05996.x
- The paper
- Thompson, P. W., Ye, L., Morgenstern, J. L., Sue, L., Beach, T. G., Judd, D. J., Shipley, N. J., Libri, V., & Lockhart, A. (2009). Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer’s disease pathologies. Journal of Neurochemistry. https://doi.org/10.1111/j.1471-4159.2009.05996.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.